Advertisement

Clinical Features, Disease Modifiers, and Natural History of Alcoholic Liver Disease

  • Luis S. Marsano
  • Vatsalya Vatsalya
  • Ammar Hassan
  • Craig J. McClainEmail author

Abstract

Alcoholic liver disease (ALD) is a major cause of morbidity and mortality worldwide. The clinical spectrum of ALD includes fatty liver, steatohepatitis with or without fibrosis, and cirrhosis. The diagnosis of ALD is made in patients with evidence of liver injury based on clinical history, physical findings, and laboratory abnormalities, when there is evidence of significant alcohol consumption and after other causes of chronic liver disease have been excluded. Signs and symptoms may be essentially nonexistent in steatosis or possibly mild fatigue and abdominal discomfort. On the other hand, those with decompensated disease may present with massive ascites, muscle wasting, gastrointestinal bleeding, and encephalopathy. Many people drink heavily, yet only a limited number (~35 %) develop more advanced liver diseases (alcoholic hepatitis or cirrhosis). Thus, there must be modifying factors that either prevent or facilitate disease activity/progression. These modifiers can either be fixed (e.g., genetic) or can undergo intervention (e.g., continued drinking, smoking, diet). We review ten disease modifiers of particular importance to ALD. Patients with steatosis only may “normalize” with cessation of drinking; however, outcomes are highly variable once the patient has progressed to cirrhosis. Some subjects die quickly with acute-on-chronic liver disease; other patients who abstain from alcohol and correct other disease modifiers may live a relatively normal life; others may do well for long periods of time only to expire from hepatocellular carcinoma. The biggest variable is continued drinking, and cessation of this and modification of other disease modifiers such as smoking should be aggressively pursued.

Keywords

Alcoholic liver disease Alcoholic cirrhosis Alcoholic hepatitis AUDIT Hepatocellular carcinoma Heavy drinking Carbohydrate-deficient transferrin 

Notes

Acknowledgments

This work was supported by NIH grants, R01AA018869 (CJM), U01AA021893 (CJM), U01AA021901 (CJM), R01AA023681 (CJM), U01AA022489 (CJM), and the Veterans Administration (CJM).

References

  1. 1.
    Carithers RL, McClain CJ. Alcoholic liver disease. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease, vol. 2. Philadelphia, PA: Elsevier Saunders; 2016. p. 1409–27.Google Scholar
  2. 2.
    Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol. 2011;45(8):714–9. doi: 10.1097/MCG.0b013e3181fdef1d.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Sandahl TD, Jepsen P, Thomsen KL, Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999–2008: a nationwide population based cohort study. J Hepatol. 2011;54(4):760–4. doi: 10.1016/j.jhep.2010.07.016.PubMedCrossRefGoogle Scholar
  4. 4.
    Chedid A, Mendenhall CL, Gartside P, French SW, Chen T, Rabin L. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol. 1991;86(2):210–6.PubMedGoogle Scholar
  5. 5.
    Force USPST. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med. 2004;140(7):554–6.CrossRefGoogle Scholar
  6. 6.
    Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7):1208–17. doi: 10.1111/j.1530-0277.2007.00403.x.PubMedCrossRefGoogle Scholar
  7. 7.
    Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. J Gen Intern Med. 2009;24(7):783–8. doi: 10.1007/s11606-009-0928-6.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA. 1984;252(14):1905–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, Schnohr P, Jensen G. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025–9. doi: 10.1002/hep.510230513.PubMedCrossRefGoogle Scholar
  10. 10.
    Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med. 1999;48(4):184–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol. 1981;10(2):417–41.PubMedGoogle Scholar
  12. 12.
    Lischner MW, Alexander JF, Galambos JT. Natural history of alcoholic hepatitis. I. The acute disease. Am J Dig Dis. 1971;16(6):481–94.PubMedCrossRefGoogle Scholar
  13. 13.
    Van Thiel DH, Gavaler JS, Schade RR. Liver disease and the hypothalamic pituitary gonadal axis. Semin Liver Dis. 1985;5(1):35–45. doi: 10.1055/s-2008-1041756.PubMedCrossRefGoogle Scholar
  14. 14.
    Dutta SK, Dukehart M, Narang A, Latham PS. Functional and structural changes in parotid glands of alcoholic cirrhotic patients. Gastroenterology. 1989;96(2 Pt 1):510–8.PubMedGoogle Scholar
  15. 15.
    Pirovino M, Linder R, Boss C, Kochli HP, Mahler F. Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations. Klin Wochenschr. 1988;66(7):298–302.PubMedCrossRefGoogle Scholar
  16. 16.
    Attali P, Ink O, Pelletier G, Vernier C, Jean F, Moulton L, Etienne JP. Dupuytren’s contracture, alcohol consumption, and chronic liver disease. Arch Intern Med. 1987;147(6):1065–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Epstein O, Dick R, Sherlock S. Prospective study of periostitis and finger clubbing in primary biliary cirrhosis and other forms of chronic liver disease. Gut. 1981;22(3):203–6.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Niemela O. Biomarkers in alcoholism. Clin Chim Acta. 2007;377(1–2):39–49. doi: 10.1016/j.cca.2006.08.035.PubMedCrossRefGoogle Scholar
  19. 19.
    Bell H, Tallaksen CM, Try K, Haug E. Carbohydrate-deficient transferrin and other markers of high alcohol consumption: a study of 502 patients admitted consecutively to a medical department. Alcohol Clin Exp Res. 1994;18(5):1103–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Yersin B, Nicolet JF, Dercrey H, Burnier M, van Melle G, Pecoud A. Screening for excessive alcohol drinking. Comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med. 1995;155(17):1907–11.PubMedCrossRefGoogle Scholar
  21. 21.
    Mundle G, Munkes J, Ackermann K, Mann K. Sex differences of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume in alcohol-dependent patients. Alcohol Clin Exp Res. 2000;24(9):1400–5.PubMedGoogle Scholar
  22. 22.
    Anton RF, Moak DH. Carbohydrate-deficient transferrin and gamma-glutamyltransferase as markers of heavy alcohol consumption: gender differences. Alcohol Clin Exp Res. 1994;18(3):747–54.PubMedCrossRefGoogle Scholar
  23. 23.
    Berlakovich GA, Soliman T, Freundorfer E, Windhager T, Bodingbauer M, Wamser P, Hetz H, Peck-Radosavljevic M, Muehlbacher F. Pretransplant screening of sobriety with carbohydrate-deficient transferrin in patients suffering from alcoholic cirrhosis. Transpl Int. 2004;17(10):617–21. doi: 10.1007/s00147-004-0765-9.PubMedCrossRefGoogle Scholar
  24. 24.
    Madhubala V, Subhashree AR, Shanthi B. Serum carbohydrate deficient transferrin as a sensitive marker in diagnosing alcohol abuse: a case - control study. J Clin Diagn Res. 2013;7(2):197–200. doi: 10.7860/JCDR/2013/5137.2726.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Hock B, Schwarz M, Domke I, Grunert VP, Wuertemberger M, Schiemann U, Horster S, Limmer C, Stecker G, Soyka M. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction. 2005;100(10):1477–86. doi: 10.1111/j.1360-0443.2005.01216.x.PubMedCrossRefGoogle Scholar
  26. 26.
    Hietala J, Koivisto H, Anttila P, Niemela O. Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol. 2006;41(5):528–33. doi: 10.1093/alcalc/agl050.PubMedCrossRefGoogle Scholar
  27. 27.
    Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S, Torella R, Persico M. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006;38(7):485–9. doi: 10.1016/j.dld.2006.03.021.PubMedCrossRefGoogle Scholar
  28. 28.
    Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology. 1980;137(3):727–9. doi: 10.1148/radiology.137.3.6934563.PubMedCrossRefGoogle Scholar
  29. 29.
    Borra RJ, Salo S, Dean K, Lautamaki R, Nuutila P, Komu M, Parkkola R. Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging. Radiology. 2009;250(1):130–6. doi: 10.1148/radiol.2501071934.PubMedCrossRefGoogle Scholar
  30. 30.
    Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed). 1986;292(6512):13–5.CrossRefGoogle Scholar
  31. 31.
    Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med. 1989;111(6):473–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Thomasson HR. Gender differences in alcohol metabolism. Physiological responses to ethanol. Recent Dev Alcohol. 1995;12:163–79.PubMedGoogle Scholar
  33. 33.
    Thomasson H. Alcohol elimination: faster in women? Alcohol Clin Exp Res. 2000;24(4):419–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Mumenthaler MS, Taylor JL, O’Hara R, Yesavage JA. Gender differences in moderate drinking effects. Alcohol Res Health. 1999;23(1):55–64.PubMedGoogle Scholar
  35. 35.
    Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med. 1990;322(2):95–9. doi: 10.1056/NEJM199001113220205.PubMedCrossRefGoogle Scholar
  36. 36.
    Seitz HK, Egerer G, Simanowski UA, Waldherr R, Eckey R, Agarwal DP, Goedde HW, von Wartburg JP. Human gastric alcohol dehydrogenase activity: effect of age, sex, and alcoholism. Gut. 1993;34(10):1433–7.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Ammon E, Schafer C, Hofmann U, Klotz U. Disposition and first-pass metabolism of ethanol in humans: is it gastric or hepatic and does it depend on gender? Clin Pharmacol Ther. 1996;59(5):503–13. doi: 10.1016/S0009-9236(96)90178-2.PubMedCrossRefGoogle Scholar
  38. 38.
    Oneta CM, Pedrosa M, Ruttimann S, Russell RM, Seitz HK. Age and bioavailability of alcohol. Z Gastroenterol. 2001;39(9):783–8. doi: 10.1055/s-2001-17196.PubMedCrossRefGoogle Scholar
  39. 39.
    Hall PM. Factors influencing individual susceptibility to alcoholic liver disease. In: Hall PM, editor. Alcoholic liver disease: pathology and pathogenesis. 2nd ed. London: Edward Arnold; 1995. p. 299–316.Google Scholar
  40. 40.
    Maher JJ. Exploring alcohol’s effects on liver function. Alcohol Health Res World. 1997;21(1):5–12.PubMedGoogle Scholar
  41. 41.
    Ikejima K, Enomoto N, Iimuro Y, Ikejima A, Fang D, Xu J, Forman DT, Brenner DA, Thurman RG. Estrogen increases sensitivity of hepatic Kupffer cells to endotoxin. Am J Physiol. 1998;274(4 Pt 1):G669–76.PubMedGoogle Scholar
  42. 42.
    Ikejima K, Enomoto N, Iimuro Y, Brenner DA, Thurman RG. Estrogen increases sensitivity of hepatic Kupffer cells to endotoxin. Alcohol Clin Exp Res. 1998;22:768–9.CrossRefGoogle Scholar
  43. 43.
    Colantoni A, La Paglia N, De Maria N, Emanuele MA, Emanuele NV, Idilman R, Harig J, Van Thiel DH. Influence of sex hormonal status on alcohol-induced oxidative injury in male and female rat liver. Alcohol Clin Exp Res. 2000;24(9):1467–73.PubMedCrossRefGoogle Scholar
  44. 44.
    Kalant H. Pharmacological interactions of aging and alcohol. NIAAA Research Monograph No. 33. In: Gomberg ESL, Hegedus AM, Zucker RA, editors. Alcohol Problems and Aging, vol NIH Publication No. Bethesda, MD: NIH publications; 1998. p. 98–4163.Google Scholar
  45. 45.
    Masson S, Emmerson I, Henderson E, Fletcher EH, Burt AD, Day CP, Stewart SF. Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease. Liver Int. 2014;34(2):235–42. doi: 10.1111/liv.12242.PubMedCrossRefGoogle Scholar
  46. 46.
    Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25(1):108–11. doi: 10.1002/hep.510250120.PubMedCrossRefGoogle Scholar
  47. 47.
    Flores YN, Yee Jr HF, Leng M, Escarce JJ, Bastani R, Salmeron J, Morales LS. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999–2004. Am J Gastroenterol. 2008;103(9):2231–8. doi: 10.1111/j.1572-0241.2008.02022.x.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Levy RE, Catana AM, Durbin-Johnson B, Halsted CH, Medici V. Ethnic differences in presentation and severity of alcoholic liver disease. Alcohol Clin Exp Res. 2015;39(3):566–74. doi: 10.1111/acer.12660.PubMedCrossRefGoogle Scholar
  49. 49.
    Sarin SK, Dhingra N, Bansal A, Malhotra S, Guptan RC. Dietary and nutritional abnormalities in alcoholic liver disease: a comparison with chronic alcoholics without liver disease. Am J Gastroenterol. 1997;92(5):777–83.PubMedGoogle Scholar
  50. 50.
    McClain CJ, Barve SS, Barve A, Marsano L. Alcoholic liver disease and malnutrition. Alcohol Clin Exp Res. 2011;35(5):815–20. doi: 10.1111/j.1530-0277.2010.01405.x.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res. 1995;19(3):635–41.PubMedCrossRefGoogle Scholar
  52. 52.
    Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, Schiff ER, McClain CJ, Marsano LS, Allen JI, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. JPEN J Parenter Enteral Nutr. 1995;19(4):258–65.PubMedCrossRefGoogle Scholar
  53. 53.
    Mendenhall CL, Tosch T, Weesner RE, Garcia-Pont P, Goldberg SJ, Kiernan T, Seeff LB, Sorell M, Tamburro C, Zetterman R, et al. VA cooperative study on alcoholic hepatitis. II: prognostic significance of protein-calorie malnutrition. Am J Clin Nutr. 1986;43(2):213–8.PubMedGoogle Scholar
  54. 54.
    Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med. 1984;76(2):211–22.PubMedCrossRefGoogle Scholar
  55. 55.
    Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Croce L, Sasso F, Pozzato G, Cristianini G, Brandi G. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41(6):845–50.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Nanji AA, French SW. Dietary linoleic acid is required for development of experimentally induced alcoholic liver injury. Life Sci. 1989;44(3):223–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther. 2001;299(2):638–44.PubMedGoogle Scholar
  58. 58.
    Nanji AA, Yang EK, Fogt F, Sadrzadeh SM, Dannenberg AJ. Medium chain triglycerides and vitamin E reduce the severity of established experimental alcoholic liver disease. J Pharmacol Exp Ther. 1996;277(3):1694–700.PubMedGoogle Scholar
  59. 59.
    Trumbo P, Schlicker S, Yates AA, Poos M, Food, Nutrition Board of the Institute of Medicine TNA. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 2002;102(11):1621–30.PubMedCrossRefGoogle Scholar
  60. 60.
    Kirpich IA, Feng W, Wang Y, Liu Y, Barker DF, Barve SS, McClain CJ. The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol Clin Exp Res. 2012;36(5):835–46. doi: 10.1111/j.1530-0277.2011.01673.x.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Kirpich IA, Feng W, Wang Y, Liu Y, Beier JI, Arteel GE, Falkner KC, Barve SS, McClain CJ. Ethanol and dietary unsaturated fat (corn oil/linoleic acid enriched) cause intestinal inflammation and impaired intestinal barrier defense in mice chronically fed alcohol. Alcohol. 2013;47(3):257–64. doi: 10.1016/j.alcohol.2013.01.005.PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Mohammad MK, Zhou Z, Cave M, Barve A, McClain CJ. Zinc and liver disease. Nutr Clin Pract. 2012;27(1):8–20. doi: 10.1177/0884533611433534.PubMedCrossRefGoogle Scholar
  63. 63.
    Zhong W, Zhao Y, Sun X, Song Z, McClain CJ, Zhou Z. Dietary zinc deficiency exaggerates ethanol-induced liver injury in mice: involvement of intrahepatic and extrahepatic factors. PLoS One. 2013;8(10), e76522. doi: 10.1371/journal.pone.0076522.PubMedCentralPubMedCrossRefGoogle Scholar
  64. 64.
    Falk DE, Yi HY, Hiller-Sturmhofel S. An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Alcohol Res Health. 2006;29(3):162–71.PubMedGoogle Scholar
  65. 65.
    Hughes JR. Treatment of smoking cessation in smokers with past alcohol/drug problems. J Subst Abuse Treat. 1993;10(2):181–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Dani JA, Harris RA. Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat Neurosci. 2005;8(11):1465–70. doi: 10.1038/nn1580.PubMedCrossRefGoogle Scholar
  67. 67.
    Enoch MA, Goldman D. The genetics of alcoholism and alcohol abuse. Curr Psychiatry Rep. 2001;3(2):144–51.PubMedCrossRefGoogle Scholar
  68. 68.
    Tyndale RF. Genetics of alcohol and tobacco use in humans. Ann Med. 2003;35(2):94–121.PubMedCrossRefGoogle Scholar
  69. 69.
    Funk D, Marinelli PW, Le AD. Biological processes underlying co-use of alcohol and nicotine: neuronal mechanisms, cross-tolerance, and genetic factors. Alcohol Res Health. 2006;29(3):186–92.PubMedGoogle Scholar
  70. 70.
    Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A. 2007;104(30):12518–23. doi: 10.1073/pnas.0705368104.PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Acheson A, Mahler SV, Chi H, de Wit H. Differential effects of nicotine on alcohol consumption in men and women. Psychopharmacology (Berl). 2006;186(1):54–63. doi: 10.1007/s00213-006-0338-y.CrossRefGoogle Scholar
  72. 72.
    Villard PH, Herber R, Seree EM, Attolini L, Magdalou J, Lacarelle B. Effect of cigarette smoke on UDP-glucuronosyltransferase activity and cytochrome P450 content in liver, lung and kidney microsomes in mice. Pharmacol Toxicol. 1998;82(2):74–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Zabala V, Tong M, Yu R, Ramirez T, Yalcin EB, Balbo S, Silbermann E, Deochand C, Nunez K, Hecht S, de la Monte SM. Potential contributions of the tobacco nicotine-derived nitrosamine ketone (NNK) in the pathogenesis of steatohepatitis in a chronic plus binge rat model of alcoholic liver disease. Alcohol Alcohol. 2015;50(2):118–31. doi: 10.1093/alcalc/agu083.PubMedCrossRefGoogle Scholar
  74. 74.
    Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992;136(10):1248–57.PubMedGoogle Scholar
  75. 75.
    Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40(6):897–903. doi: 10.1016/j.jhep.2004.02.010.PubMedCrossRefGoogle Scholar
  76. 76.
    Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14. doi: 10.1001/jama.2014.732.PubMedCrossRefGoogle Scholar
  77. 77.
    Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–41. doi: 10.1001/jama.2009.2014.PubMedCrossRefGoogle Scholar
  78. 78.
    Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979;67(5):811–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Dietz WH. The response of the US Centers for Disease Control and Prevention to the obesity epidemic. Annu Rev Public Health. 2015;36:575–96. doi: 10.1146/annurev-publhealth-031914-122415.PubMedCrossRefGoogle Scholar
  80. 80.
    Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology. 2000;118(6):1117–23.PubMedCrossRefGoogle Scholar
  81. 81.
    Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–40.PubMedCrossRefGoogle Scholar
  82. 82.
    Mavrelis PG, Ammon HV, Gleysteen JJ, Komorowski RA, Charaf UK. Hepatic free fatty acids in alcoholic liver disease and morbid obesity. Hepatology. 1983;3(2):226–31.PubMedCrossRefGoogle Scholar
  83. 83.
    Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, Naveau S. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002;35(3):635–8. doi: 10.1053/jhep.2002.31782.PubMedCrossRefGoogle Scholar
  84. 84.
    Stickel F, Osterreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol. 2006;41(3):209–24. doi: 10.1093/alcalc/agl011.PubMedCrossRefGoogle Scholar
  85. 85.
    Dolganiuc A, Petrasek J, Kodys K, Catalano D, Mandrekar P, Velayudham A, Szabo G. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res. 2009;33(10):1704–10. doi: 10.1111/j.1530-0277.2009.01007.x.PubMedCentralPubMedCrossRefGoogle Scholar
  86. 86.
    Meng F, Glaser SS, Francis H, Yang F, Han Y, Stokes A, Staloch D, McCarra J, Liu J, Venter J, Zhao H, Liu X, Francis T, Swendsen S, Liu CG, Tsukamoto H, Alpini G. Epigenetic regulation of miR-34a expression in alcoholic liver injury. Am J Pathol. 2012;181(3):804–17. doi: 10.1016/j.ajpath.2012.06.010.PubMedCentralPubMedCrossRefGoogle Scholar
  87. 87.
    Tang Y, Banan A, Forsyth CB, Fields JZ, Lau CK, Zhang LJ, Keshavarzian A. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res. 2008;32(2):355–64. doi: 10.1111/j.1530-0277.2007.00584.x.PubMedCrossRefGoogle Scholar
  88. 88.
    Lu SC, Mato JM. Role of methionine adenosyltransferase and S-adenosylmethionine in alcohol-associated liver cancer. Alcohol. 2005;35(3):227–34. doi: 10.1016/j.alcohol.2005.03.011.PubMedCrossRefGoogle Scholar
  89. 89.
    Bonsch D, Lenz B, Reulbach U, Kornhuber J, Bleich S. Homocysteine associated genomic DNA hypermethylation in patients with chronic alcoholism. J Neural Transm. 2004;111(12):1611–6. doi: 10.1007/s00702-004-0232-x.PubMedCrossRefGoogle Scholar
  90. 90.
    Bonsch D, Lenz B, Fiszer R, Frieling H, Kornhuber J, Bleich S. Lowered DNA methyltransferase (DNMT-3b) mRNA expression is associated with genomic DNA hypermethylation in patients with chronic alcoholism. J Neural Transm. 2006;113(9):1299–304. doi: 10.1007/s00702-005-0413-2.PubMedCrossRefGoogle Scholar
  91. 91.
    Lambert MP, Paliwal A, Vaissiere T, Chemin I, Zoulim F, Tommasino M, Hainaut P, Sylla B, Scoazec JY, Tost J, Herceg Z. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol. 2011;54(4):705–15. doi: 10.1016/j.jhep.2010.07.027.PubMedCrossRefGoogle Scholar
  92. 92.
    Kirpich I, Ghare S, Zhang J, Gobejishvili L, Kharebava G, Barve SJ, Barker D, Moghe A, McClain CJ, Barve S. Binge alcohol-induced microvesicular liver steatosis and injury are associated with down-regulation of hepatic Hdac 1, 7, 9, 10, 11 and up-regulation of Hdac 3. Alcohol Clin Exp Res. 2012;36(9):1578–86. doi: 10.1111/j.1530-0277.2012.01751.x.PubMedCrossRefGoogle Scholar
  93. 93.
    Park PH, Miller R, Shukla SD. Acetylation of histone H3 at lysine 9 by ethanol in rat hepatocytes. Biochem Biophys Res Commun. 2003;306(2):501–4.PubMedCrossRefGoogle Scholar
  94. 94.
    Lee YJ, Shukla SD. Histone H3 phosphorylation at serine 10 and serine 28 is mediated by p38 MAPK in rat hepatocytes exposed to ethanol and acetaldehyde. Eur J Pharmacol. 2007;573(1–3):29–38. doi: 10.1016/j.ejphar.2007.06.049.PubMedCentralPubMedCrossRefGoogle Scholar
  95. 95.
    Aroor AR, James TT, Jackson DE, Shukla SD. Differential changes in MAP kinases, histone modifications, and liver injury in rats acutely treated with ethanol. Alcohol Clin Exp Res. 2010;34(9):1543–51. doi: 10.1111/j.1530-0277.2010.01239.x.PubMedCentralPubMedCrossRefGoogle Scholar
  96. 96.
    James TT, Aroor AR, Lim RW, Shukla SD. Histone H3 phosphorylation (Ser10, Ser28) and phosphoacetylation (K9S10) are differentially associated with gene expression in liver of rats treated in vivo with acute ethanol. J Pharmacol Exp Ther. 2012;340(2):237–47. doi: 10.1124/jpet.111.186775.PubMedCentralPubMedCrossRefGoogle Scholar
  97. 97.
    Cave M, Falkner KC, Ray M, Joshi-Barve S, Brock G, Khan R, Bon Homme M, McClain CJ. Toxicant-associated steatohepatitis in vinyl chloride workers. Hepatology. 2010;51(2):474–81. doi: 10.1002/hep.23321.PubMedCentralPubMedCrossRefGoogle Scholar
  98. 98.
    Bao L, Shi H. Potential molecular mechanisms for combined toxicity of arsenic and alcohol. J Inorg Biochem. 2010;104(12):1229–33. doi: 10.1016/j.jinorgbio.2010.08.005.PubMedCrossRefGoogle Scholar
  99. 99.
    Mailloux RJ, Florian M, Chen Q, Yan J, Petrov I, Coughlan MC, Laziyan M, Caldwell D, Lalande M, Patry D, Gagnon C, Sarafin K, Truong J, Chan HM, Ratnayake N, Li N, Willmore WG, Jin X. Exposure to a northern contaminant mixture (NCM) alters hepatic energy and lipid metabolism exacerbating hepatic steatosis in obese JCR rats. PLoS One. 2014;9(9), e106832. doi: 10.1371/journal.pone.0106832.PubMedCentralPubMedCrossRefGoogle Scholar
  100. 100.
    McClain CJ, Holtzman J, Allen J, Kromhout J, Shedlofsky S. Clinical features of acetaminophen toxicity. J Clin Gastroenterol. 1988;10(1):76–80.PubMedCrossRefGoogle Scholar
  101. 101.
    Kumar S, Rao PS, Earla R, Kumar A. Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert Opin Drug Metab Toxicol. 2015;11(3):343–55. doi: 10.1517/17425255.2015.996546.PubMedCentralPubMedCrossRefGoogle Scholar
  102. 102.
    Pontes H, Duarte JA, de Pinho PG, Soares ME, Fernandes E, Dinis-Oliveira RJ, Sousa C, Silva R, Carmo H, Casal S, Remiao F, Carvalho F, Bastos ML. Chronic exposure to ethanol exacerbates MDMA-induced hyperthermia and exposes liver to severe MDMA-induced toxicity in CD1 mice. Toxicology. 2008;252(1–3):64–71. doi:10.1016/j.tox.2008.07.064.PubMedCrossRefGoogle Scholar
  103. 103.
    Lee M, Kowdley KV. Alcohol’s effect on other chronic liver diseases. Clin Liver Dis. 2012;16(4):827–37. doi: 10.1016/j.cld.2012.08.010.PubMedCrossRefGoogle Scholar
  104. 104.
    Punzalan CS, Bukong TN, Szabo G. Alcoholic hepatitis and HCV interactions in the modulation of liver disease. J Viral Hepat. 2015. doi: 10.1111/jvh.12399.PubMedGoogle Scholar
  105. 105.
    Gleeson D, Evans S, Bradley M, Jones J, Peck RJ, Dube A, Rigby E, Dalton A. HFE genotypes in decompensated alcoholic liver disease: phenotypic expression and comparison with heavy drinking and with normal controls. Am J Gastroenterol. 2006;101(2):304–10. doi: 10.1111/j.1572-0241.2006.00439.x.PubMedCrossRefGoogle Scholar
  106. 106.
    Fletcher L, Powell L. Hemochromatosis and alcoholic liver disease. Alcohol. 2003;30:131–6.PubMedCrossRefGoogle Scholar
  107. 107.
    European Association for the Study of the Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57(2):399–420.CrossRefGoogle Scholar
  108. 108.
    Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol. 2015;12(4):231–42. doi: 10.1038/nrgastro.2015.35.PubMedCrossRefGoogle Scholar
  109. 109.
    Pateria P, de Boer B, MacQuillan G. Liver abnormalities in drug and substance abusers. Best Pract Res Clin Gastroenterol. 2013;27(4):577–96. doi: 10.1016/j.bpg.2013.08.001.PubMedCrossRefGoogle Scholar
  110. 110.
    Mathurin P, Beuzin F, Louvet A, Carrie-Ganne N, Balian A, Trinchet JC, Dalsoglio D, Prevot S, Naveau S. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther. 2007;25(9):1047–54. doi: 10.1111/j.1365-2036.2007.03302.x.PubMedCrossRefGoogle Scholar
  111. 111.
    Rubin E, Lieber CS. Alcohol-induced hepatic injury in nonalcoholic volunteers. N Engl J Med. 1968;278(16):869–76. doi: 10.1056/NEJM196804182781602.PubMedCrossRefGoogle Scholar
  112. 112.
    Lieber CS, Rubin E. Alcoholic fatty liver in man on a high protein and low fat diet. Am J Med. 1968;44(2):200–6.PubMedCrossRefGoogle Scholar
  113. 113.
    MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis. 1986;6(3):221–32. doi: 10.1055/s-2008-1040605.PubMedCrossRefGoogle Scholar
  114. 114.
    Ma C, Brunt EM. Histopathologic evaluation of liver biopsy for cirrhosis. Adv Anat Pathol. 2012;19(4):220–30. doi: 10.1097/PAP.0b013e31825c6bab.PubMedCrossRefGoogle Scholar
  115. 115.
    Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011;141(5):1572–85. doi: 10.1053/j.gastro.2011.09.002.PubMedCentralPubMedCrossRefGoogle Scholar
  116. 116.
    Said A, Holden JP, Williams JB, Musat A, Botero RC, Lucey MR. Model for end stage liver disease (MELD) scores predict mortality across a broad spectrum of liver disease in a us tertiary care-setting. Gastroenterology 124(4): A690–1. doi:10.1016/S0016-5085(03)83493-5Google Scholar
  117. 117.
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70. doi: 10.1053/jhep.2001.22172.PubMedCrossRefGoogle Scholar
  118. 118.
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–71. doi: 10.1053/he.2000.5852.PubMedCrossRefGoogle Scholar
  119. 119.
    Freeman Jr RB, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, Merion R, Wolfe R, Turcotte J, Teperman L, Unos/Optn Liver Disease Severity Score UOL, Intestine, Committees UOPT. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8(9):851–8. doi: 10.1053/jlts.2002.35927.PubMedCrossRefGoogle Scholar
  120. 120.
    Maddrey WC, Boitnott JK, Bedine MS, Weber Jr FL, Mezey E, White Jr RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75(2):193–9.PubMedGoogle Scholar
  121. 121.
    Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut. 1982;23(1):75–9.PubMedCentralPubMedCrossRefGoogle Scholar
  122. 122.
    Carithers Jr RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989;110(9):685–90.PubMedCrossRefGoogle Scholar
  123. 123.
    Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, Fisher NC, Singhal S, Brind A, Haydon G, O’Grady J, Day CP, Hayes PC, Murray LS, Morris AJ. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54(8):1174–9. doi: 10.1136/gut.2004.050781.PubMedCentralPubMedCrossRefGoogle Scholar
  124. 124.
    Dominguez M, Rincon D, Abraldes JG, Miquel R, Colmenero J, Bellot P, Garcia-Pagan JC, Fernandez R, Moreno M, Banares R, Arroyo V, Caballeria J, Gines P, Bataller R. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008;103(11):2747–56. doi: 10.1111/j.1572-0241.2008.02104.x.PubMedCrossRefGoogle Scholar
  125. 125.
    Model L. Accessed 04/07/15 2015. 2015.Google Scholar
  126. 126.
    Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45(6):1348–54. doi: 10.1002/hep.21607.PubMedCrossRefGoogle Scholar
  127. 127.
    Jalan R, Pavesi M, Saliba F, Amoros A, Fernandez J, Holland-Fischer P, Sawhney R, Mookerjee R, Caraceni P, Moreau R, Gines P, Durand F, Angeli P, Alessandria C, Laleman W, Trebicka J, Samuel D, Zeuzem S, Gustot T, Gerbes AL, Wendon J, Bernardi M, Arroyo V, Investigators CS, Consortium E-C. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol. 2015;62(4):831–40. doi: 10.1016/j.jhep.2014.11.012.PubMedCrossRefGoogle Scholar
  128. 128.
    Zhang Q, Li Y, Han T, Nie C, Cai J, Liu H, Liu Y. Comparison of current diagnostic criteria for acute-on-chronic liver failure. PLoS One. 2015;10(3), e0122158. doi: 10.1371/journal.pone.0122158.PubMedCentralPubMedCrossRefGoogle Scholar
  129. 129.
    Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, Arroyo V, Kamath PS. Acute-on chronic liver failure. J Hepatol. 2012;57(6):1336–48. doi: 10.1016/j.jhep.2012.06.026.PubMedCrossRefGoogle Scholar
  130. 130.
    Jalan R, Yurdaydin C, Bajaj JS, Acharya SK, Arroyo V, Lin HC, Gines P, Kim WR, Kamath PS, World Gastroenterology Organization Working Party. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. 2014;147(1):4–10. doi: 10.1053/j.gastro.2014.05.005.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Luis S. Marsano
    • 1
    • 2
    • 3
  • Vatsalya Vatsalya
    • 1
    • 2
  • Ammar Hassan
    • 1
    • 2
  • Craig J. McClain
    • 1
    • 2
    • 3
    • 4
    Email author
  1. 1.Division of Gastroenterology, Hepatology and NutritionUniversity of LouisvilleLouisvilleUSA
  2. 2.Department of MedicineUniversity of LouisvilleLouisvilleUSA
  3. 3.Robley Rex Veterans Affairs Medical CenterLouisvilleUSA
  4. 4.Department of Pharmacology & ToxicologyUniversity of Louisville School of MedicineLouisvilleUSA

Personalised recommendations